Clinical Trial of Pancreatic Cancer in Stockholm.
SPP
Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors.
1 other identifier
observational
600
1 country
1
Brief Summary
SPP study includes incidence cases of pancreatic cancer in the Stockholm county region from 2007 to 2014. The purpose of SPP study is to estimate relative risk of pancreatic cancer in relation to snuff dipping, overweight/obesity, individual food items, food groups, dietary pattern and various nutrients; to estimate relative risk of pancreatic cancer in relation to exposure to nitrosamines, either endogenously or exogenously; to estimate relative risk of pancreatic cancer in relation to oral health and H.pylori infection and their interaction with ABO blood type; to estimation relative risk of pancreatic cancer in relation to hepatitis B or hepatitis C infection; to estimate relative risk of pancreatic cancer in relation to some genetic polymorphisms, either functional or being suggested in GWAS study; to estimate mutation profile in pancreatic cancer cases, and its correlation with environmental exposures, and the impacts on survival periods in pancreatic cancer patients. The MeSH name is Carcinoma, Pancreatic Ductal
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2007
CompletedFirst Submitted
Initial submission to the registry
June 11, 2014
CompletedFirst Posted
Study publicly available on registry
June 13, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedOctober 24, 2023
October 1, 2023
9.8 years
June 11, 2014
October 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival
5 years
Secondary Outcomes (1)
Factors influencing survival
5 years
Study Arms (1)
Pancreatic cancer
Patients with pancreatic cancer and age\&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
Interventions
Surgical removal of the pancreatic tumour (cancer) in the intervention group
Eligibility Criteria
Population based cohort of all patients with pancreatic cancer within the district of Stockholm and age and gender matched healthy controls.
You may qualify if:
- pancreatic cancer patients that aged less than 85 years old born in Sweden living in Stockholm
- written informed consent
You may not qualify if:
- pancreatic cancer older than 85 years
- pancratic cancer younger than 18 years
- not willing to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Karolinska University Hospital, Gastrocentrum
Stockholm, 14186, Sweden
Related Publications (4)
Yu J, Song H, Ekheden I, Lohr M, Ploner A, Ye W. Gastric Mucosal Abnormality and Risk of Pancreatic Cancer: A Population-Based Gastric Biopsy Cohort Study in Sweden. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2088-2095. doi: 10.1158/1055-9965.EPI-21-0580. Epub 2021 Sep 8.
PMID: 34497088RESULTMolina-Montes E, Van Hoogstraten L, Gomez-Rubio P, Lohr M, Sharp L, Molero X, Marquez M, Michalski CW, Farre A, Perea J, O'Rorke M, Greenhalf W, Ilzarbe L, Tardon A, Gress TM, Barbera VM, Crnogorac-Jurcevic T, Munoz-Bellvis L, Dominguez-Munoz E, Balsells J, Costello E, Iglesias M, Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Ye W, Hidalgo M, Carrato A, Lawlor R, Real FX, Malats N; PanGenEU Study Investigators. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):1009-1018. doi: 10.1158/1055-9965.EPI-19-1027. Epub 2020 Feb 12.
PMID: 32051190RESULTYu J, Ploner A, Kordes M, Lohr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int J Cancer. 2021 Apr 15;148(8):2048-2058. doi: 10.1002/ijc.33464. Epub 2021 Jan 15.
PMID: 33411965RESULTMolina-Montes E, Coscia C, Gomez-Rubio P, Fernandez A, Boenink R, Rava M, Marquez M, Molero X, Lohr M, Sharp L, Michalski CW, Farre A, Perea J, O'Rorke M, Greenhalf W, Iglesias M, Tardon A, Gress TM, Barbera VM, Crnogorac-Jurcevic T, Munoz-Bellvis L, Dominguez-Munoz JE, Renz H, Balcells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Hidalgo M, Lawlor RT, Ye W, Carrato A, Real FX, Malats N; PanGenEU Study Investigators. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Gut. 2021 Feb;70(2):319-329. doi: 10.1136/gutjnl-2019-319990. Epub 2020 May 14.
PMID: 32409590RESULT
Biospecimen
Germline DNA and tumour DNA (PDAC patients). Saliva and urine (DNA).
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matthias Löhr, Professor
Karolinska University Hospital
- STUDY DIRECTOR
Magnus Nilsson, ass prof
Karolinska University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 11, 2014
First Posted
June 13, 2014
Study Start
May 1, 2007
Primary Completion
February 1, 2017
Study Completion
February 1, 2017
Last Updated
October 24, 2023
Record last verified: 2023-10